Engelsk titel: Osteoporosis in castration therapy - a neglected field
Läs online
Författare:
Bratt, Ola
;
Åkesson, Kristina
Email: ola.bratt@skane.se
Språk: Swe
Antal referenser: 27
Dokumenttyp:
Översikt
UI-nummer: 11101039
Sammanfattning
Androgen deprivation therapy is the cornerstone of treatment for metastatic prostate cancer. Although osteoporosis and increased fracture risk are established side-effects of such therapy since more than a decade, few Swedish prostate cancer patients are presently investigated and treated for osteoporosis. Skeletal metastases from prostate cancer are common. It is thus essential that bone health is maintained for these patients. This article includes a review of the published studies in the field and their clinical consequences. Patients with other risk factors for fractures should have a bone densitometry within the first months of androgen deprivation therapy. For patients without osteoporosis the densitometry should be repeated within a few years. When osteoporosis is diagnosed treatment should follow the general principles for osteoporotic patients. Patients treated with corticosteroids for more than three months should always receive prophylactic therapy for osteoporosis. First line therapy is peroral alendronate, vitamin D and calcium supplements.